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Replication of Associations of Genetic Loci Outside the HLA
Region With Susceptibility to Anti–Cyclic Citrullinated
Peptide–Negative Rheumatoid Arthritis
Sebastien Viatte,1 Jonathan Massey,1 John Bowes,1 Kate Duffus,1 arcOGEN Consortium,
Stephen Eyre,1 Anne Barton,2 and Jane Worthington2
Objective. Genetic polymorphisms within the
HLA region explain only a modest proportion of anti–
cyclic citrullinated peptide (anti-CCP)–negative rheu-
matoid arthritis (RA) heritability. However, few non-
HLA markers have been identified so far. This study
was undertaken to replicate the associations of anti-
CCP–negative RA with non-HLA genetic polymorphisms
demonstrated in a previous study.
Methods. The Rheumatoid Arthritis Consortium
International densely genotyped 186 autoimmune-
related regions in 3,339 anti-CCP–negative RA patients
and 15,870 controls across 6 different populations using
the Illumina ImmunoChip array. We performed a case–
control replication study of the anti-CCP–negative
markers with the strongest associations in that discovery
study, in an independent cohort of anti-CCP–negative
UK RA patients. Individuals from the arcOGEN
Consortium and Wellcome Trust Case Control Consor-
tium were used as controls. Genotyping in cases was
performed using Sequenom MassArray technology.
Genome-wide data from controls were imputed using
the 1000 Genomes Phase I integrated variant call set
release version 3 as a reference panel.
Results. After genotyping and imputation quality
control procedures, data were available for 15 non-HLA
single-nucleotide polymorphisms in 1,024 cases and
6,348 controls. We confirmed the known markers
ANKRD55 (meta-analysis odds ratio [OR] 0.80;
P5 2.8 3 10213) and BLK (OR 1.13; P5 7.0 3 1026)
and identified new and specific markers of anti-CCP–
negative RA (prolactin [PRL] [OR 1.13; P5 2.1 3
1026] and NFIA [OR 0.85; P5 2.5 3 1026]). Neither of
these loci is associated with other common, complex
autoimmune diseases.
Conclusion. Anti-CCP–negative RA and anti-
CCP–positive RA are genetically different disease sub-
sets that only partially share susceptibility factors.
Genetic polymorphisms located near the PRL and NFIA
genes represent examples of genetic susceptibility fac-
tors specific for anti-CCP–negative RA.
Rheumatoid arthritis (RA) can be categorized as
seronegative or seropositive, based on the presence or
absence of anti–citrullinated protein autoantibodies
(ACPAs). Most ACPA-positive RA patients are positive
for anti–cyclic citrullinated peptide (anti-CCP) anti-
bodies, a hallmark that is used to classify RA patients
according to the 2010 American College of Rheumatol-
ogy (ACR)/European League Against Rheumatism
classification criteria (1). Although the two serotypes
are not clinically distinguishable at diagnosis, the pres-
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ence of anti-CCP antibodies at baseline predicts the future
development of erosive disease (2,3). Debate continues as
to whether anti-CCP–positive and anti-CCP–negative RA
actually represent two distinct diseases, with a common
clinical end point of synovial inflammation (4–9).
The contribution of genetic factors to the suscep-
tibility of each serotype was estimated to be equivalent
in a small twin study (10); however, in a recent study
using large population-representative samples, the heri-
tability calculation was revised and reported to be 50% for
anti-CCP–positive RA and 20% for anti-CCP–negative
RA (11). Although it was initially thought that HLA did
not play a role in the etiology of anti-CCP–negative RA
(12), several studies have now shown its association with
seronegative disease (5,8,13,14). More recently, this asso-
ciation has been pinpointed to 2 amino acid positions
within HLA molecules: position 11 of HLA–DRB1 and
position 9 of HLA–B (15). Based on the small number of
susceptibility loci identified within the HLA region and
their relatively small effect sizes, it is unlikely that they
completely explain the disease heritability of seronegative
RA. Non-HLA markers of anti-CCP–negative RA are
therefore likely to exist.
However, candidate gene and genome-wide asso-
ciation studies (GWAS) of seronegative RA have identi-
fied few non-HLA determinants of anti-CCP–negative
RA at confirmed levels of statistical significance. Most
genetic associations specific for anti-CCP–negative RA
have been reported in single studies and have not been
independently replicated. We have previously tested
markers of anti-CCP–positive RA for their association
with anti-CCP–negative RA (8) and reported that sever-
al anti-CCP–positive RA susceptibility loci (e.g., AFF3,
CCR6, CCL21, IL2RA, and CD28) were not shared with
anti-CCP–negative RA, while markers at TNFAIP3,
C5orf30, STAT4, ANKRD55, BLK, and PTPN22 were
associated with both anti-CCP–positive and anti-CCP–
negative RA. In addition, CLYBL (14), SMIM21 (14),
SPP1 (16), CLEC16A (17), IRF5 (18), and DCIR (19,20)
have been reported to be associated with anti-CCP–
negative RA. Of the markers reported to be associated with
anti-CCP–negative RA, only CLYBL (14), SMIM21 (14),
and ANKRD55 (21) have been independently replicated or
confirmed at genome-wide levels of significance.
In a previous study of 11,475 RA cases and
15,870 controls genotyped for 129,464 markers using the
ImmunoChip array, we identified 14 new RA suscepti-
bility loci reaching a genome-wide level of significance
(21). In a subset analysis of the 3,339 anti-CCP–negative
RA cases, only rs71624119 mapping to intron 6 of
ANKRD55 reached genome-wide significance levels out-
side the HLA region, although other variants showed
suggestive levels of association. Therefore, in the pre-
sent study, we tested these variants in an independent
cohort of anti-CCP–negative RA cases and controls to
identify replicated susceptibility loci.
PATIENTS AND METHODS
Cohorts and patients. For the replication study, sam-
ples were obtained from 1,044 UK RA patients who did not
take part in the ImmunoChip study, satisfied the 1987 ACR
classification criteria for RA (22), and tested negative for anti-
CCP, as determined with the second-generation CCP (CCP2)
assay. These patients were selected from the Norfolk Arthritis
Register, Rheumatoid Arthritis Medication Study, National
Repository, and Biologics in RA Genetics and Genomics
Study Syndicate (Table 1). Individuals from the Wellcome
Trust Case Control Consortium 2 (WTCCC2) and from the
arcOGEN study were used as controls. (See Appendix A for a
list of arcOGEN Consortium members and their affiliations.)
Individuals from the WTCCC2 who were used as controls in
the ImmunoChip study were identified using identity by
descent calculation and removed. The arcOGEN cohort com-
prised 7,410 unrelated patients with severe osteoarthritis (OA)
(23). We excluded arcOGEN cases from Nottingham because
those patients had only provided informed consent for partici-
pation in studies related to OA. Consequently, 5,459 arc-
OGEN cases were available as additional controls in our
study. Informed consent was obtained from all patients, and
ethics approval was obtained from all relevant institutional
ethics committees.
Selection of single-nucleotide polymorphisms (SNPs).
The patients and methods used to identify non-HLA genetic
polymorphisms associated with anti-CCP–negative RA in the
Table 1. Summary of cohort characteristics*
Cohort No. of patients No. (%) female† Criteria for diagnosis Anti-CCP–negative, %
BRAGGSS 296 225 (78) 1987 ACR criteria for RA 100
NR 24 23 (96) 1987 ACR criteria for RA 100
RAMS 119 80 (67) 1987 ACR criteria for RA 100
NOAR 585 369 (67) 1987 ACR criteria for RA 100
Total 1,024 – – –
* Anti-CCP5 anti–cyclic citrullinated peptide; BRAGGSS5Biologics in Rheumatoid Arthritis Genetics and
Genomics Study Syndicate; ACR5American College of Rheumatology; RA5 rheumatoid arthritis; NR5
National Repository; RAMS5Rheumatoid Arthritis Medication Study; NOAR5Norfolk Arthritis Register.
† Percentage of the individuals for whom information on sex was available.
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discovery study (ImmunoChip) have been described previously
(21). Briefly, 3,339 anti-CCP–negative cases (Supplementary
Table 1 in ref. 21) were compared to 15,870 controls. Cases
and controls were obtained from 6 different cohorts (UK,
Swedish Epidemiological Investigation of Rheumatoid Arth-
ritis, US, Dutch, Spanish, and Swedish Umea) and genotyped
on the ImmunoChip platform (186 regions densely mapped
with 44,973 individual SNPs between the densely mapped
regions [singletons]). When the ImmunoChip array was
designed, the densely mapped regions were included if they
had previously shown strong evidence of association with at
least one autoimmune disease, while less stringent evidence
was available for singletons. Effect sizes were meta-analyzed
across the 6 cohorts as previously described (21). There were
1,000 anti-CCP–negative RA cases and 8,430 controls originat-
ing from the UK on the ImmunoChip (UK ImmunoChip
cohort). In order to select SNPs for the replication study pre-
sented here, we first excluded the HLA region (segment 25–
35Mb on chromosome 6); then, the SNP with the lowest associa-
tion P value for anti-CCP–negative RA was selected for every
densely mapped region or for every linkage disequilibrium block
(r25 0.8) between the regions. Finally, 2 sets of SNPs were
selected, based on the following P thresholds: 1) SNPs with
P, 1.0 3 1024 for anti-CCP–negative patients from the meta-
analysis of the 6 ImmunoChip cohorts; and 2) SNPs with P# 3.0
3 1024 for anti-CCP–negative patients from the UK Immuno-
Chip cohort.
Genotyping. Control data were available from both
the WTCCC2, genotyped on Affymetrix version 6.0 and an
Illumina 1.2M platform, and from arcOGEN samples, geno-
typed using Illumina Human610-Quad BeadChips (23). Geno-
typing of anti-CCP–negative RA cases in the replication
cohort was performed using a Sequenom MassArray platform
according to the manufacturer’s instructions. SNPs that failed
genotyping on Sequenom or accurate calling were first
removed. Patients with a genotyping rate of ,90% and SNPs
with a success rate of ,90% were removed, together with
SNPs with a minor allele frequency (MAF) of ,5%.
Imputation. In order to impute genotypes for the
WTCCC2, data sets from Affymetrix version 6.0 and the Illu-
mina 1.2M platform were merged. Data from the WTCCC2
and arcOGEN were phased with SHAPEIT version 2 and
imputed with IMPUTE2 using the 1000 Genomes Phase I
integrated variant call set release version 3. Imputed probabili-
ties were replaced by the best guess genotypes using the
default threshold at 0.9. No INFO score cutoff was applied.
Additional postimputation quality control was performed
selectively for the replication SNPs using the same thresholds
as applied for the genotyping quality controls described above
for cases.
Statistical analysis. Association study. Association
testing with anti-CCP–negative RA was performed with Plink
version 1.07 (24) using a basic allelic chi-square test. The fol-
lowing strategy was applied to meta-analyze the results from
the discovery and replication studies: for the set of SNPs with
P, 1.0 3 1024 for anti-CCP–negative patients from the meta-
analysis of the 6 ImmunoChip cohorts, results from the repli-
cation study were considered to be a seventh cohort and a
Table 2. Results of the replication study*
Replication
Meta-analysis
(anti-CCP–
negative RA)†
ImmunoChip
study (anti-CCP–
positive RA)‡
Ratio of OR for
anti-CCP–positive
RA to OR for anti-
CCP–negative RA
from the
ImmunoChip
study§
Chr. SNP ID Gene Selected OR (95% CI) P OR P OR P Ratio P
5 rs71624119 ANKRD55 BOTH 0.85 (0.76–0.96) 6.0 3 1023¶ 0.80 2.8 3 10213 0.84 1.7 3 10211 1.07 8.2 3 1022
6 rs10440835 PRL IC 1.14 (1.04–1.26) 8.1 3 1023¶ 1.13 2.1 3 1026 1.05 2.5 3 1022 0.93 2.8 3 1022
5 rs528092 C5orf30 IC 0.92 (0.83–1.01) 8.9 3 1022 0.89 3.3 3 1026 0.92 5.0 3 1024 1.06 6.4 3 1022
8 rs4840565 BLK IC 1.12 (1.01–1.24) 2.9 3 1022 1.13 7.0 3 1026 1.09 3.4 3 1024 0.97 0.33
16 rs28698667 IL27 IC 1.06 (0.97–1.17) 0.21 1.11 6.3 3 1025 1.02 0.32 0.91 5.0 3 1023
21 rs9979383 RUNX1 IC 0.96 (0.88–1.06) 0.47 0.91 2.0 3 1024 0.91 3.2 3 1025 1.02 0.55
18 rs16955629 RAB31 IC 1.03 (0.92–1.15) 0.62 1.11 2.1 3 1024 1.02 0.34 0.91 1.0 3 1022
2 rs10181656 STAT4 IC 1.04 (0.93–1.16) 0.50 1.11 2.2 3 1024 1.14 2.4 3 1027 1.00 0.90
2 rs888427 CYBRD1 IC 0.95 (0.86–1.05) 0.34 1.08 2.0 3 1023 – – – –
1 rs10489912 NFIA UK 0.87 (0.79–0.96) 3.8 3 1023¶ 0.85 2.5 3 1026 0.97 0.17 1.06 4.8 3 1022
1 rs2249707 SLAMF9 UK 0.99 (0.90–1.10) 0.89 0.90 6.5 3 1023 1.02 0.30 1.09 5.6 3 1023
17 rs2689 HNF1B UK 1.04 (0.94–1.14) 0.47 0.93 3.3 3 1022 – – – –
4 rs6533712 CAMK2D UK 0.93 (0.85–1.02) 0.12 1.05 0.12 – – – –
11 rs613587 FLI1 UK 0.89 (0.80–0.99) 3.2 3 1022 1.05 0.15 – – – –
* After quality control procedures, the genotypes of 14 single-nucleotide polymorphisms (SNPs) were analyzed in the replication phase in 1,024
anti–citrullinated protein autoantibody (anti-CCP)–negative rheumatoid arthritis (RA) cases and 6,348 controls. Chr.5 chromosome; OR5odds
ratio; 95% CI5 95% confidence interval.
† Meta-analysis of discovery (ImmunoChip [IC]) and replication cohorts.
‡ Meta-analysis across the 6 cohorts of the ImmunoChip study of the association with anti-CCP–positive RA.
§ A ratio of 1.0 indicates that the effect size is the same for anti-CCP–positive RA and anti-CCP–negative RA. The P value for the ratio indicates
whether a genetic marker is significantly differentially associated between the 2 disease subsets. The comparison with anti-CCP–positive RA was
performed only if the direction of the effect size for anti-CCP–negative RA was consistent between the discovery and replication studies.
¶ Significant after Bonferroni correction (P, 0.01).
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fixed-effects meta-analysis with inverse variance weighting was
applied across the 7 studies (or cohorts); for the set of SNPs
with P# 3.0 3 1024 for anti-CCP–negative patients from the
UK ImmunoChip cohort, results from the replication study
were combined for meta-analysis only with results from the
UK cohort of the ImmunoChip study.
Correction for multiple testing. The P values reported
for the replication study were not corrected for multiple test-
ing. Significance was assessed using a stringent Bonferroni cor-
rection for multiple testing. The number of independent tests
was determined independently for each of the SNP sets
described above after exclusion of positive controls (i.e., SNPs
previously reported to be associated with anti-CCP–negative
RA: BLK, STAT4, C5orf30, and ANKRD55). We tested 5
SNPs from the UK ImmunoChip cohort (Table 2). None of
the SNPs in this set had been previously reported to be associ-
ated with anti-CCP–negative RA. Therefore, the Bonferroni
corrected threshold for significance for this SNP set was 0.05/5
tests (P, 0.01). There were 8 SNPs from the meta-analysis of
the 6 ImmunoChip cohorts (Table 2); 3 SNPs in this SNP set
(C5orf30, BLK, and STAT4) had previously been reported to
be associated with anti-CCP–negative RA. Therefore, the
Bonferroni corrected threshold for significance for this SNP set
was 0.05/(82 3) tests (P, 0.01). The Bonferroni corrected
threshold for significance in this replication study was therefore
set at P, 0.01 for any SNP tested. Considering the 2 sets of
SNPs as independent experiments is a valid working hypothesis,
since they barely overlap and they do not contain the same pro-
portion of already identified markers of anti-CCP–negative RA,
which could be explained by population-specific associations.
Establishing the specificity of anti-CCP–negative asso-
ciations. When the direction of the effect size for anti-CCP–
negative RA was consistent between the discovery and replication
studies, the effect size for anti-CCP–negative RA was formally
compared with the effect size for anti-CCP–positive RA. A multi-
nomial logistic regression was applied in the discovery Immuno-
Chip study to compute odds ratios (ORs), 95% confidence
intervals (95% CIs), and P values for association between the
minor allele of every SNP and either anti-CCP–positive RA or
anti-CCP–negative RA, assuming additivity on the log-odds scale.
To test for differences between OR for anti-CCP–positive RA
and OR for anti-CCP–negative RA, the linear combination
b12b2, where b1 is log(OR for anti-CCP–positive RA) and
b2 is log(OR for anti-CCP–negative RA), was calculated, along
with its standard error. The P value for the difference in associa-
tion between anti-CCP–positive RA and anti-CCP–negative RA
was then calculated. Statistical analysis was performed with Stata
version 12.1 (StataCorp) at the High Performance Computing
facility of The University of Manchester.
Calculation of a genetic risk score (GRS) and receiver
operating characteristic (ROC) analysis. GRS calculation and
ROC curve analysis (including the calculation of the area
under the ROC curve [AUC]) were performed according to
the method of Karlson and as described previously (25,26).
Briefly, the GRS was calculated as the sum of the risk allele
counts, weighted by the natural logarithm of the OR. Since
ORs are usually inflated in the discovery cohort (“winner’s
curse” effect), we computed the GRS using ORs calculated
from the replication study presented here. The association of
the GRS with anti-CCP–negative RA was tested by logistic
regression. Clinical usefulness was evaluated with ROC curve
analysis and calculation of the AUC using Stata.
RESULTS
Selection of SNPs for the replication study. SNPs
selected from the meta-analysis of the 6 ImmunoChip
cohorts and SNPs selected from the UK ImmunoChip
cohort are presented in Table 3. SNP rs71624119
mapping to the ANKRD55 locus was the only SNP that
reached genome-wide significance for anti-CCP–
negative RA in the ImmunoChip study (i.e., P below the
threshold for genome-wide significance at P5 5.0 3
1028) and was the only SNP in common between the
top hits from the meta-analysis and from the UK Immu-
noChip cohort (Table 3). This SNP was therefore used
as a positive control in our replication study. Among the
13 SNPs selected from the UK ImmunoChip cohort,
only CLEC16A had previously been reported to be asso-
ciated with anti-CCP–negative RA (17), but other
SNPs/genes (for example STAT4, BLK, and C5orf30)
were not among the best hits in this cohort. They were,
however, among the 12 SNPs selected from the meta-
analysis across the 6 ImmunoChip cohorts. Other
markers reported to be associated with anti-CCP–
negative RA (i.e., PTPN22) were not among the best
hits from the meta-analysis. The majority of the markers
selected for replication (Table 3) are represented by
SNPs lying outside regions densely genotyped on the
ImmunoChip, i.e., outside regions expected to be associ-
ated with autoimmune diseases.
Genotyping results for anti-CCP–negative RA
cases and controls. DNA samples from UK anti-CCP–
negative RA patients (n5 1,044) were genotyped for 19
SNPs; 2 SNPs failed to genotype, and 1 was excluded in
postgenotyping quality control. Twenty patient samples
were excluded based on their low genotyping rate. After
quality control, the genotypes for 16 SNPs were avail-
able in 1,024 anti-CCP–negative RA patients (Table 1).
The total genotyping rate was 99.95%, and all SNPs
were in Hardy-Weinberg equilibrium. After imputation
and quality control procedures, 5,283 individuals who
were diagnosed as having OA from the arcOGEN Con-
sortium and 4,766 control individuals from the
WTCCC2 with available genome-wide genotypes were
available as controls for the present study, with a total
genotyping rate of 99.42%. Data for 15 of the 16 SNPs
successfully genotyped in cases could be analyzed in
controls (Tables 2 and 3).
Significant differences in MAFs between
WTCCC2 and arcOGEN data sets for any of the 15
SNPs of interest could indicate either population strat-
ification at these loci, a specific association with OA,
or imputation error. It has previously been reported
that there is very little population stratification within
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the UK (27), and when we compared the MAFs of the
15 SNPs of interest between the WTCCC2 and arc-
OGEN samples, only 1 SNP, rs4736558 on chromosome
8, showed any difference in MAF (uncorrected P 5
0.010) (Table 4), and that SNP was removed. Therefore,
we concluded that the WTCCC2 and arcOGEN samples
could be merged and used together as controls. After
removal of 3,701 WTCCC2 samples that were already
used as controls in the ImmunoChip study, a total of
6,348 controls were available for analysis, together with
1,024 cases. Therefore, 8 SNPs from the ImmunoChip
meta-analysis and 5 SNPs from the UK ImmunoChip
cohort were available for replication analysis.
Results of statistical analysis. Results of the
analysis are presented in Table 2. As expected,
rs71624119 (ANKRD55) was associated with anti-
CCP–negative RA (OR 0.85; P5 6.0 3 1023) in the
replication cohort (Table 2). Of the 14 SNPs tested, 10
showed a consistent direction of association between
the discovery and replication data sets (OR consistent-
ly greater than or less than 1.0). Among these, 3 SNPs
near PRL, NFIA, and BLK were associated with
Table 4. Comparison of MAFs of SNPs in the arcOGEN and WTCCC2 cohorts*
Chr. SNP
MAF in
arcOGEN
cases (n5 5,283)
MAF in
WTCCC2 controls
(n5 4,766) OR (95% CI)
1 rs10489912 0.42 0.42 1.01 (0.96–1.07)
1 rs2249707 0.31 0.31 1.00 (0.94–1.06)
2 rs888427 0.36 0.36 1.02 (0.96–1.08)
2 rs10181656 0.23 0.22 1.04 (0.98–1.11)
4 rs6533712 0.48 0.47 1.04 (0.99–1.10)
5 rs71624119 0.24 0.24 1.02 (0.95–1.09)
5 rs528092 0.33 0.33 1.00 (0.95–1.06)
6 rs10440835 0.34 0.33 1.03 (0.97–1.09)
8 rs4840565 0.28 0.27 1.02 (0.96–1.08)
8† rs4736558 0.24 0.23 1.09 (1.02–1.16)
11 rs613587 0.30 0.29 1.04 (0.97–1.10)
16 rs28698667 0.41 0.42 0.98 (0.93–1.04)
17 rs2689 0.49 0.48 1.02 (0.96–1.08)
18 rs16955629 0.24 0.24 1.02 (0.96–1.09)
21 rs9979383 0.38 0.37 1.01 (0.95–1.07)
* WTCCC25Wellcome Trust Case Control Consortium 2; Chr.5 chromosome; OR5 odds ratio; 95%
CI5 95% confidence interval.
† The single-nucleotide polymorphism (SNP) rs4736558 on chromosome 8 was the only SNP that
showed any difference in minor allele frequency (MAF) (uncorrected P value5 0.010) and was exclud-
ed from the analysis.
Table 5. Quality of imputation or genotyping of SNPs presented in Table 2*
arcOGEN WTCCC2 Anti-CCP–negative RA cases
Chr. SNP ID Gene INFO† Type INFO† Type Genotyping rate, %‡
1 rs10489912 NFIA 1.00 Directly typed 1.00 Directly typed 99.8
1 rs2249707 SLAMF9 1.00 Directly typed 1.00 Directly typed 99.9
2 rs10181656 STAT4 0.99 Imputed 1.00 Imputed 100
2 rs888427 CYBRD1 1.00 Directly typed 1.00 Directly typed 99.9
4 rs6533712 CAMK2D 0.99 Imputed 1.00 Directly typed 100
5 rs71624119 ANKRD55 0.98 Imputed 0.97 Imputed 100
5 rs528092 C5orf30 1.00 Imputed 1.00 Imputed 100
6 rs10440835 PRL 0.99 Imputed 1.00 Directly typed 99.9
8 rs4840565 BLK 0.99 Imputed 1.00 Imputed 100
11 rs613587 FLI1 1.00 Directly typed 1.00 Directly typed 100
16 rs28698667 IL27 1.00 Directly typed 1.00 Imputed 99.8
17 rs2689 HNF1B 0.99 Imputed 1.00 Imputed 100
18 rs16955629 RAB31 1.00 Directly typed 1.00 Directly typed 100
21 rs9979383 RUNX1 1.00 Directly typed 1.00 Directly typed 99.9
* SNPs5 single-nucleotide polymorphisms; Chr.5 chromosome; WTCCC25Wellcome Trust Case Control Consortium 2.
† Postimputation INFO score.
‡ Number of anti–citrullinated protein (anti-CCP)–negative rheumatoid arthritis (RA) patients in the replication data set (UK) with available
genotype information after quality control, divided by the total number of individuals (n5 1,024).
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P, 0.05 in the replication data set. The significance of
associations for SNPs near PRL and NFIA persisted
after correction for multiple testing. The association
of rs10440835 (near PRL) is very unlikely to be driven by
the known association with HLA (15), since rs10440835 is
not in linkage disequilibrium with the HLA region
(r2, 0.001 between rs10440835 and the HLA–
DRB1*0401 tag SNP rs6910071, calculated in the Immuno-
Chip data set). All other associations shown in Table 2 are
also independent of the HLA, since they arose from genetic
markers that are not located on chromosome 6. The associ-
ation statistics presented in Table 2 are unlikely to arise
from low imputation quality, since most SNPs were directly
genotyped in controls or had an INFO score of .0.97 if
imputed (Table 5).
Meta-analysis. For SNPs selected from the
UK ImmunoChip cohort, the meta-analysis was per-
formed between that cohort and the replication
cohort, while for SNPs selected from the meta-
analysis of the 6 ImmunoChip populations, the meta-
analysis was performed between those 6 populations
and the UK replication cohort, which was treated as a
seventh population. Meta-analysis increased the con-
fidence in the true nature of the association of
ANKRD55 with anti-CCP–negative RA (OR 0.80; 2.8 3
10213) (Table 2). Similarly, the association statistics
were strengthened for several SNPs, in particular for
PRL (OR 1.13; P5 2.1 3 1026) and NFIA (OR 0.85;
2.5 3 1026), increasing the confidence that they repre-
sent true associations.
Comparison of associations with anti-CCP–
negative RA and associations with anti-CCP–positive
RA. The comparison of the association of ANKRD55
with anti-CCP–positive samples and the association of
ANKRD55 with anti-CCP–negative samples showed that
the ANKRD55 polymorphism is shared between the 2
serotypes (Table 2). The same was observed for BLK: the
ratio of the effect size between the 2 serotypes was not
significantly different from 1.00. However, PRL and
NFIA SNPs were not associated with anti-CCP–positive
RA and were significantly differentially associated
between the 2 serotypes, suggesting that they represent
specific anti-CCP–negative associations (Table 2).
GRS and ROC analysis. A GRS was computed
with all known and newly identified non-HLA genetic
markers of anti-CCP–negative RA available in this study
(Table 2): ANKRD55, PRL, C5orf30, BLK, STAT4, and
NFIA. As expected, the GRS was associated with anti-
CCP–negative RA (OR 2.74 [95% CI 1.92–3.91])
(P5 2.41 3 1028). The ROC curve is presented in
Figure 1; the AUC was 0.55.
DISCUSSION
The ImmunoChip study (21) represents the larg-
est study of genetic markers of seronegative RA to date,
but only the HLA region and the ANKRD55 locus
showed confirmed association in anti-CCP–negative RA
patients (i.e., below the threshold for genome-wide sig-
nificance at P5 5.0 3 1028). However, there were a
number of variants that showed suggestive levels of
association, and here we report the results of a replica-
tion study in an independent group of RA cases and
controls from the UK. We have identified 2 loci that
show replicated evidence of association in anti-CCP–
negative disease.
The first locus, rs10440835, is located on chro-
mosome 6 in the intergenic domain between the prolac-
tin (PRL) and the neurensin 1 (NRSN1) gene. SNP
rs10440835 is not known to be associated with anti-
CCP–positive RA at a genome-wide level of signifi-
cance, is situated 7 Mb away from the center of the
HLA region, and is not in linkage disequilibrium with
HLA. Therefore, the association of rs10440835 is
unlikely to be confounded by HLA associations.
Although the PRL region was not densely genotyped on
the ImmunoChip, prolactin has been the focus of stud-
ies in RA over many decades (28). Prolactin plays a pre-
dominant role in lactation in the postpartum period,
and parity and breastfeeding are both associated with
RA susceptibility (29). Hyperprolactinemia is observed
in a proportion of patients with RA (30,31). Prolactin is
Figure 1. Receiver operating characteristic (ROC) curve analysis for
a genetic risk score calculated for ANKRD55, PRL, C5orf30, BLK,
STAT4, and NFIA. The area under the curve is 0.5532; clinical utility
can therefore be achieved only if other markers (genetic and/or envi-
ronmental) can be incorporated. Color figure can be viewed in the
online issue, which is available at http://onlinelibrary.wiley.com/journal/
doi/10.1002/art.39619/abstract.
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secreted from the pituitary gland as well as other organs
and cells, including lymphocytes. It acts both as a hor-
mone and a cytokine to regulate the function of a variety
of tissues, including immune cells and cartilage (32).
The modification of prolactin levels has been suggested
to have therapeutic potential in RA (32). Among the
immunomodulatory functions of prolactin, this hor-
mone has been reported to increase tumor necrosis fac-
tor expression in the peripheral CD141 monocytes of
patients with RA (33). However, no genetic association
with RA susceptibility was found in the PRL region in
the latest and largest RA susceptibility study published
to date, comprising predominantly anti-CCP–positive
RA (34).
The second locus, rs10489912, is located on chro-
mosome 1 in an intron of nuclear factor I/A (NFIA), a
member of the NF-1 family of transcription factors.
NFIA has been shown to regulate the production,
differentiation, and/or function of several immune
cell subsets, including granulocytes (35), monocyte/
macrophages (36), and CD3142CD158a1 natural killer
cells (37), which are all immune cell subsets of the
innate immune system. An association of the NFIA
locus with a form of RA without antibodies is interest-
ing, since the production of anti-CCP antibodies
requires the engagement of the adaptive immune system
(T and B lymphocytes).
Interestingly, the majority of SNPs that had sug-
gestive levels of association and were selected for repli-
cation testing from the ImmunoChip study mapped
outside classical autoimmune-related regions. These are
unexpected findings because genetic markers of auto-
immune diseases are largely shared with at least one
other trait (38). Although our novel findings for anti-
CCP–negative disease (PRL and NFIA) are exceptions
to the general trend of cross-disease traits, our study
provides evidence that they are unlikely to be false posi-
tives. BLK, C5orf30, and STAT4 have already been
reported to be associated with seronegative RA in inde-
pendent studies, 10 of 14 SNPs showed a consistent direc-
tion of association, and the 2 newly identified markers,
located near the PRL and NFIA genes, showed statistical-
ly significant evidence of independent replication.
The novel associations at PRL and NFIA add to
the list of suggestive or confirmed anti-CCP–negative
RA susceptibility loci: PTPN22, TNFAIP3, C5orf30,
STAT4, BLK (8), SPP1 (16), CLEC16A (17), IRF5 (18),
DCIR (19,20), CLYBL (14), SMIM21 (14), and
ANKRD55 (21). However, only a few of those associa-
tions have been independently replicated or confirmed at
genome-wide levels of significance. With over 4,300 anti-
CCP–negative samples (in the discovery and replication
cohorts together), the present study is the largest world-
wide. If the genetic architecture of anti-CCP–negative
RA were similar to that of anti-CCP–positive RA with
regard to the total number of SNPs conferring suscepti-
bility and their effect sizes, our study should have been as
successful as equivalently well-powered studies of anti-
CCP–positive RA, as performed;5 years ago.
However, it appears clear that the effect sizes
detected in this study are small and the strength of associ-
ation (P value) does not reach the threshold for genome-
wide significance. This could be partially explained by the
fact that the genetic contribution to anti-CCP–negative
RA susceptibility is lower than the heritability of anti-
CCP–positive RA, but it is likely to also reflect the hetero-
geneity of anti-CCP–negative RA (39). If anti-CCP–
negative RA comprises several different clinical subsets,
each caused by different sets of SNPs, the identification of
susceptibility SNPs without knowledge of the yet unidenti-
fied subsets (39) will be difficult, and limited to SNPs
shared between the most prevalent subsets. The develop-
ment of new genetic methodologies is therefore required
to define genetically distinct disease subsets that cannot
simply be classified clinically or based on serologic tests.
Ultimately, the identification of genetic markers
of disease susceptibility will lead to personalized or
stratified medicine in rheumatology. We have recently
shown that the strongest genetic markers of RA suscepti-
bility are also the strongest markers of RA course, severi-
ty, and mortality and possibly response to treatment with
biologic agents (40). Therefore, the current identification
of genetic susceptibility markers of RA subsets is likely to
affect our future ability to guide clinical decisions based
on the patient’s personal genetic profile.
The goal of our study was to identify new genetic
markers of anti-CCP–negative RA and not to determine
the cumulative predictive capacity of all already-known
markers, including those recently identified within the
HLA region (15). Therefore, the genotypes at those loci
were not all available in our replication cohort. None-
theless, we were able to consider the effect and predic-
tive capacity of a set of SNPs (ANKRD55, PRL, C5orf30,
BLK, STAT4, and NFIA); though their aggregate associ-
ation with anti-CCP–negative RA is important (OR 2.74
[95% CI 1.92–3.91]) (P5 2.41 3 1028), their predictive
capacity remains very low (AUC 0.55). We have already
shown for anti-CCP–positive RA, for which the total
number and effect size of genetic susceptibility markers
identified so far are much larger than for anti-CCP–
negative RA, that 1) the predictive value of an aggregate
GRS including all known markers is too low to be used
in a clinical setting (26); and 2) the inclusion of non-
HLA SNPs into a GRS exclusively based on HLA
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markers did not significantly affect its predictive capaci-
ty (26). We show in the present study that the total num-
ber and effect sizes of anti-CCP–negative loci are
smaller than for anti-CCP–positive RA; therefore, a
much larger number of loci will need to be identified
before their use can enter the clinic.
Our study therefore represents an important step
in the development of genetically based algorithms for
stratified medicine in rheumatology, since it highlights
important limitations of the “single SNP” approach. We
show that, for anti-CCP–negative RA, as is the case for
any other heterogeneous or rare autoimmune disease
phenotype, our current experimental approaches reach
their limitations. Even well-powered studies using data
from large international consortia fail to identify a suffi-
ciently large number of susceptibility polymorphisms at
genome-wide significance that could explain a sufficiently
large proportion of disease heritability to permit stratifi-
cations of individuals into different risk strata for person-
alized medicine. Therefore, the experimental approach
of researchers in genetics of complex diseases needs to
be changed from the identification of single SNPs (either
through candidate gene approaches or GWAS) to statis-
tical strategies identifying much larger sets of SNPs (pos-
sibly thousands) at the same time. Using a Bayesian
inference analysis of the polygenic architecture of RA,
Stahl et al (41) have already shown that, together, thou-
sands of SNPs from RA GWAS would explain an addi-
tional 20% of disease risk, excluding known associated
loci. Therefore, with new statistical techniques to come
and further increase in sample sizes through internation-
al collaborations, the identification of much larger sets of
anti-CCP–negative RA associations and their use in com-
puting clinically meaningful patient stratification algo-
rithms for personalized medicine remains an achievable
goal for the future.
Therefore, we can conclude that 1) non-HLA
genetic markers of anti-CCP–negative RA do exist, 2) in
general, their effect size is smaller than susceptibility
markers for anti-CCP–positive RA (meaning that larger
sample sizes are required for detection), 3) they might
not be preferentially located in autoimmune-related
genetic regions previously associated with other com-
plex autoimmune diseases, 4) anti-CCP–negative RA is
likely to comprise several genetically distinct disease
entities, and 5) increasing sample size and developing
new analytical approaches are further required in the
future before genetic and environmental diagnostic
scores or scores predicting disease course, severity, or
treatment response can enter clinical practice (stratified
or personalized medicine).
Although further studies are required to defini-
tively confirm the association reported here, our results
provide evidence that anti-CCP–negative and anti-
CCP–positive RA represent two genetically distinct dis-
ease subsets. The two disease subsets should therefore
be investigated separately in future genetic studies aim-
ing to identify pathogenic or causative pathways, which
are likely to be different between the two serotypes.
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APPENDIX A: THE arcOGEN CONSORTIUM
Contributors from the arcOGEN Consortium are as fol-
lows: John Loughlin (Musculoskeletal Research Group, Institute
of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne,
UK), Nigel Arden (Botnar Research Centre, University of Oxford,
and Nuffield Orthopaedic Centre, Oxford, UK), Fraser Birrell (Mus-
culoskeletal Research Group, Institute of Cellular Medicine, Newcastle
University, Newcastle upon-Tyne, and Northumbria Healthcare NHS
Foundation Trust, Wansbeck General Hospital, UK), Andrew Carr
(Botnar Research Centre, University of Oxford, and Nuffield Ortho-
paedic Centre, Oxford, UK), Panos Deloukas (William Harvey
Research Institute, Barts and The London School of Medicine and
Dentistry, Queen Mary University, London, UK and Princess Al-
Jawhara Al-Brahim Centre of Excellence in Research of Hereditary
Disorders [PACER-HD], King Abdulaziz University, Jeddah, Saudi
Arabia), Michael Doherty (Academic Rheumatology, School of
Medicine, University of Nottingham, Nottingham, UK), Andrew W.
McCaskie (Division of Trauma and Orthopaedic Surgery, Depart-
ment of Surgery, University of Cambridge, Cambridge, UK and
Musculoskeletal Research Group, Institute of Cellular Medicine,
Newcastle University, Newcastle-upon-Tyne, UK), William E. R.
Ollier (Centre for Integrated Genomic Medical Research, University
of Manchester, Manchester, UK), Ashok Rai (Worcestershire Acute
Hospitals NHS Trust, Worcester, UK), Stuart H. Ralston (Centre
for Genomic and Experimental Medicine, Institute of Genetics and
Molecular Medicine, University of Edinburgh, Edinburgh, UK), Tim
D. Spector (Department of Twin Research and Genetic Epidemiolo-
gy, King’s College London, London, UK), Ana M. Valdes (Academ-
ic Rheumatology, School of Medicine, University of Nottingham,
Nottingham, UK), Gillian A. Wallis (Wellcome Trust Centre for
Cell Matrix Research, University of Manchester, Manchester UK),
J. Mark Wilkinson (Department of Oncology and Metabolism,
University of Sheffield, Sheffield, UK), and Eleftheria Zeggini
(Wellcome Trust Sanger Institute, Wellcome Genome Campus,
Hinxton, UK).
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